The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
As I continue to review the CMS deal and CFDA (China FDA) in greater detail I suspect that the Chinese regulators have specific lines of approvals for new drugs unlike those with the EU and Stateside. As I posted last week, the CFDA allows results of clinical trials conducted in other nations to weigh in on their decision to issue NDA within Chinese markets. Further CMS or China Medical System Holdings Limited which is now primary stake holder 77% of Midatech has been ramping it's deals over the past 3-4 years. Probably in a combined effort to secure newer BIO and Pharma technologies to market internally to its Asian markets. CMS has a secure foothold within the market arena for Asia and most likely already knows the fastest and most predictable route to NDA through its CFDA and subsidiaries. Of course this is merely based on my on review, due diligence and reading numerous articles associated with China's desire to build it's Pharma and drug base in the world and pursue a dominant foothold. Lot's of newbies here now, but the older posters know I hold a fair sized tranche and have patience to wait this out which is why I'm doing more and more research on the Chinese agreement and their regulators for NDA approvals. Finally I will add in my own words that Mr. Kong now firmly invested here as largest owner along with Woodford will likely not let this fail, will in all likelihood see this through to profitability and likely provide buy side support over in the states to prop this up in $1.00 range to ensure continued listing over there. Much in play now and as others like NtoMichu have said it's more compelling now and looks much more promising now that we have this Chinese partnership. All of course just my own personal 2 cents, and I will continue to dive deeper into the regulatory china and large UK pharma partner whom are testing this as well. Please DYOR and look into all of the possibilities that these recent partnerships provide yourself. Good luck to all....it's nearly time for me pint's and back to more reading..
Been reading up on differences with the China drug approval as compared to the UK and over in the states. One particular note i've read from the China version of the FDA is as follows:
" One proposal, released for public comment on 20 October 2017 states that chinese pharma companies will be allowed to use data from clinical trials conducted in other countries when applying for drug approval in China. "
I find this to be particularly interesting, it might not mean anything or that this is the plan for the quicker approval of 201 or 110 but it also might. I'm merely saying that CMS might be allowed or authorized to use the existing data from the Phase I & II data to accelerate approval. Who knows, but thought it was an interesting read non the less. Okay it's Friday & time for me Pints and F&C's maybe I can dart out before the rain,, GLTA
Monitored L2 and trading was halted stateside...for 20 minutes
Ooopps it would post so I submitted it too many time, clearly my mistake.
If we're trying to equate the AIM share price to the states we'd be looking at 23.5 pence at the moment, but clearly we're not that hi so the states Nasdaq or AIM will likely need to correct sometime in order to balance the share price. However we all should wish and hope that their nasdaq continues higher and reaches $1.00 so that a reverse split would not enter into the equation..
If we're trying to equate the AIM share price to the states we'd be looking at 23.5 pence at the moment, but clearly we're not that hi so the states Nasdaq or AIM will likely need to correct sometime in order to balance the share price. However we all should wish and hope that their nasdaq continues higher and reaches $1.00 so that a reverse split would not enter into the equation..
If we're trying to equate the AIM share price to the states we'd be looking at 23.5 pence at the moment, but clearly we're not that hi so the states Nasdaq or AIM will likely need to correct sometime in order to balance the share price. However we all should wish and hope that their nasdaq constinues higher and reaches $1.00 so that a reverse split would not enter into the equation which would affect all.
If we're trying to equate the AIM share price to the states we'd be looking at 23.5 pence at the moment, but clearly we're not that hi so the states Nasdaq or AIM will likely need to correct sometime in order to balance the share price. However we all should wish and hope that their nasdaq constinues higher and reaches $1.00 so that a reverse split would not enter into the equation which would affect all.
If we're trying to equate the AIM share price to the states we'd be looking at 23.5 pence at the moment, but clearly we're not that hi so the states Nasdaq or AIM will likely need to correct sometime in order to balance the share price. However we all should wish and hope that their nasdaq constinues higher and reaches $1.00 so that a reverse split would not enter into the equation which would affect all.
Dave you're misinformed regarding the ADR's stateside. To be clear once again this is the correct ratio regarding the share differences.
Two ordinary AIM shares of MTPH represents one American Depository Receipt (ADR) of MTP. This is the actual ratio and should be clear from the company website, but I understand the confusion. If someone in the states had for example 10,000 ADR's then that would equate to 20,000 regular AIM shares in the company. Hope this helps, also looked stateside before their market even opens and looks like they've traded million shares and this will go higher over there today. Wouldn't be at all surprised to see this nearing $0.75 cents over the pond.
I did me share there NtoMu....Me likes the pints and while I generally wait to have them with me F&C's on Friday I did indulge a modest bit today like you did. No harm in a couple :)
In summary all presented resolutions were duly passed and their over subscribed on the offering. Three board members stepped down, one was added. Most directors and CEO took up additional shares on the offer increasing their own holdings and adding skin in the game so to speak. So with the coffers now fully stuffed with added cash, they're all poised to move ahead with about $13 million on the books. Time to roll up the sleeves and get to work, in honest opinion this was a much needed shot in the arm, but any failures to deliver moving forward would be catastrophic in my onion. Okay good luck to all, let's see some constant updates and progressive movement from here..
Silver that wasn't me :) that's too rich for my blood, my purchase was much more modest but it adds to my already tidy sum and lowered me average.
I believe once the special shareholders meeting has completed and all resolutions have passed then most likely two things are in order, The first will be an RNS with the results and a corporate update with the new shares listed, board director changes and the such, Secondly we will likely see something in the way of an announcement regarding which direction the clinical testing will go and any other u[dates on the 201 and 110 programs. As for the listing over in the states that's something of a concern that will need to be addressed and communicated shortly or within the next 30 days or so, As for the revamped company yes its leaner and hopefully more focused now and should now buckle down and deliver on its promises made to the shareholders. this new infusion of cash had better sustain them through the clinical trials and if salaries need to be further cut or assets sold off or whatever is necessary to get these clinical trials completed then I hope they do so, As for me I rounded up my mountain of shares on Friday to a nice even number and I wont plan to add any additional shares now until I see sustained improvement. Also the company has to plan the year end results and hold a conference call to review them so lots more updates coming in months ahead. Good luck to all..
Silver - I'd suspect that a market cap listed is all shares out in hands and multiplied by the share price. So it would be inclusive of the states. Further as I suspect that in reading the RNS yet again in greater detail regarding the risk of losing the listing in the states on the Nasdaq and reviewing the language it's my suspicion that the management will not allow the listing to go away. I don't know what they've planned to do about it but they have a couple of months to address it. My own suspicions or personal view is that with all of the added shares artificially inflating the share count of issued shares is they the management may elect to merge the shares or reverse split therefore increasing the share price and decreasing the share count. This is merely my own suspicion or hunch nothing more but it would resolve the matter and retain the listing. I suspect with the 110 clinical trials going on in the states California and New York plus coupled with the fact that the management is consulting with the FDA also in the sates and the fact that Nasdaq is well respected and established platform for trading that they'd not want to give up that listing option. Again my own personal option based on the dire reading from that section of the RNS the wording sounds much like that of the voting so if they don't do something those ADR shares will be hard to trade. Anyway the market cap over in the sates shows the company is like all almost 4 million market cap I think as that can be sought by searching the Nasdaq listing but one has to drop the h in the listing to just ordinary MTP.. Good luck chaps I hope this all works out for us all.
N2MU - All good points indeed. Yes it would seem that they could also convert to aim and trade as well. Yes I'd agree with most of this, however the management also wants FDA approval and that would mean that the market in the states in the future will want to trade this.....Don't know what may happen but I do know it's Friday and time for me Pint's and F&C's... Guess we'll see sometime in the near future.
Good Point, in addition if your read the 74 page release in its entirety you'd also presume that since the Nasdaq listing is of utmost importance more so than AIM, that the chaps who have their shares listed in the states wont be able to trade if the listing requirements aren't met. That would likely mean one of two scenarios, the first is that the S/P must get above $1 for a sustained period of time, currently about $0.12 cents or so. To do this a stock merger would be required to lower the total share count and raise the average cost. Not a goof move for anyone as it will lower everyone's share count, else the chaps over there could issue a class action law suit as they're unable to access and trade. Just saying not suggesting that this could or will happen but just saying t's getting dire. If a merger of stock were to occur it's in the management best interest to get the current stock price as high as possible now to lessen the harshness of the reverse split. that really is not in my mind the best answer so I'd like to see some news to get the share price elevated. Any thoughts on what a potential stock merger would be ratio wise?
N2MU...thanks for trying, but will let my broker explain this to me ( for every one share you hold you're entitled to .318 shares at 3.85p and you get a warrant for each share you take too ) if I am entitled to take up .318 of a share or shares for roughly at 3.85p + an warrant exercisable at 50p me broker will explain it. I'm appreciative of the effort there. My exit price will far exceed the warrant strike. I'd hope for 500p as that was about the price when it debuted about 2014. that would get me a smart return and ensure a comfy lifestyle.
Thanks for the insight, it cleared the part about the 0.318 ratio for 1 outstanding at 3.85p appreciate that piece. However the average bloat can buy all they want as well on the open today at 3.85p so other than getting an extra third of a share it's about the same. More important is just how this all plays out, that is what I'm paying the price of admission for. I want to see the products 201 and 110 succeed, help others, attract attention, attract a buyer and ger acquisition for eight figures paying me off handsomely for my mountain of shares....ahh to dream, but this exact scenario has a plausible place in reality, thus I'm sticking around and will participate by funding a few thousand more shares on top of me current tranche....seriously good luck to all. I may be throwing good money after bad or not, time will tell.
Specifically based on the offer current shareholders are not entitled to anything other than an 0.318 Open Offer Units (comprising one Open Offer Share and one Warrant) for every 1 Existing Ordinary Share held by the Qualifying Shareholder on the Record Date.
But what specifically does this entitlement mean? and how does one participate?